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Abstract
Background: The development of chemo-resistance in non-small lung cancer is a major obstacle in treating patients.
Hypoxia is a commonly faced microenvironment in solid tumor and suggested to be related to both autophagy and
chemo-resistance.
Methods: In this study, we investigated the role of hypoxia-induced autophagy in acquiring chemo-resistance in both
cancer cell (A549) and human cancer tissue
Results: Hypoxic exposure (1 % O2) of A549 cell stimulated autophagic induction in cancer cells, shown by increase of
LC3BI to LC3BII conversion and decrease of p62/sequestosome1 in Western blot, increased GFP-LC puncta in confocal
microscopy, and increased number of double-membrane autophagic vacuoles in electron micrographs. Hypoxic
exposure also induced resistance of cancer cells to cisplatin, and LC3B siRNA restored the sensitivity of cancer cells to
chemotherapy. Furthermore, Human lung cancer tissues that experienced chemotherapy showed increase of LC3BI to
LC3BII conversion and decrease of p62/sequestosome1 compared with chemo-naïve cancer tissue in Western blot.
Conclusion: Autophagy may play an important role in acquiring resistance to chemotherapy in lung cancer and
hypoxia related pathway seems to be involved in autophagy induction.
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Introduction
Lung cancer is a common cause of cancer-related death
worldwide [1]. Non-small cell lung cancer (NSCLC) com-
poses more than 80 % of lung cancer and chemotherapy is
a major treatment option for NSCLC patients. However,
even the best regimens have an overall response rate of
only 30–50 %. This poor response to chemotherapy leads
to the treatment failure in lung cancer.
Autophagy is considered to have dual functions in
cancer as both a tumor suppressor and a protector of
tumor cell survival [2, 3]. Before a tumor develops, au-
tophagy suppresses the tumor; however, once the tumor
begins to develop, autophagy supports the tumor in
harsh microenvironments. Some studies found that au-
tophagy is up-regulated in response to cancer treat-
ments, and protects tumor cells by contributing to the
development of treatment resistance. This observation
implies that pharmacological modulation of autophagy
can be a therapeutic target for tumor cells [2–6].
Tumor cells often face hasher microenvironments
than normal cells. Hypoxia occurs in 90 % of solid tu-
mors because angiogenesis in tumor cannot supply rap-
idly growing tumor masses with enough oxygen [7–10].
Hypoxia also influences several cancer-related pathways
including angiogenesis signaling, cell migration, energy
metabolism, cell growth, and damage deoxyribonucleic
acid (DNA) repair. Recent studies found relationships
between hypoxia-related pathways and autophagy acti-
vation. These relationships include oxygen-dependent
stabilization of hypoxia-inducible factor 1-alpha (HIF-1α)
transcription factor, inhibition of the mammalian target of
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rapamycin (mTOR) kinase signaling pathway and activa-
tion of the unfolded protein response (UPR) [11–13].
HIF-1α is the main regulator of transcription during hyp-
oxia. HIF-1α overexpression is frequently observed in
tumors and is considered to contribute to tumor cell
growth and survival by controlling both glycolysis and
angiogenesis. However, the effect of autophagy in tumor
cells under hypoxia is not fully understood.
We hypothesized that hypoxia-induced autophagy might
contribute to the resistance of NSCLC cells to chemothera-
peutic agents by decreasing their apoptotic potential and
enhancing their survival. To test this hypothesis, we studied
the effect of hypoxia on tumor cells treated with chemo-
therapeutic agents and analyzed the effects of autophagy.
Furthermore, to support our hypothesis, we measured
HIF-1α expression in tumor tissues and autophagy markers
in tumor tissues obtained from NSCLC patients.
Materials and methods
Cell lines and cultures
The A549 human lung cancer cell line was from the
Korean Cell Line Bank just before use and it wasn’t
validated again. A549 cells were maintained as monolayers
in RPMI 1640 medium (GIBCOBRL, Gaithersburg, MD,
USA) containing 10 % fetal bovine serum, 100 U/ml
penicillin (Thermo Scientific, Rockford, IL, USA) and
0.1 mg/ml streptomycin (Thermo Scientific,) at 37.0 °C
under 5 % CO2.
Reagents
The chemotherapeutic agent cisplatin (Sigma, St. Louis,
MO, USA) was dissolved in RPMI 1640 medium to pro-
duce a stock solution (1 mM) and added directly to
media at indicated concentrations.
Hypoxia treatment
For induction of hypoxic conditions, cells (1 × 104 cells/
well) were seeded in 96-well flat-bottomed plates overnight,
then incubated in hypoxia incubator (Forma Scientific,
Ohio, USA) with 1 % O2.
MTT colorimetric assays
To investigate the influence of hypoxia on cancer cell che-
mosensitivity, A549 cells were seeded in 96-well plates at
1 × 104 cells/well and cultured in 1 % hypoxia or normoxia
in medium containing cisplatin as indicated. Cell viability
was examined with MTT assay kits (Sigma). Spectrophoto-
metric absorbance was measured using a plate reader at
570 nm. All experiments were carried out in triplicate.
Transient transfection and identification of autophagy
A549 cells were seeded (6.25 × 105 cells/well) in 6-well
plates overnight, and a GFP-LC3 expressing plasmid was
transiently transfected into cells using Lipofectamine LTX
Reagent (Invitrogen, Carlsbad, CA, USA), according to
the manufacturer’s instructions. After 24 h and verifying
the expression of GFP-LC3, cells were subjected to
hypoxia (1 % O2) for 8 h. After exposure, autophagy
(GFP-LC3-positive dots) was counted (GFP-LC3-positive
dots) under a confocal laser microscope, LSM700 (Carl
Zeiss, Jena, Germany).
Electron microscopy
Samples were fixed with 2 % glutaraldehyde-
paraformaldehyde in 0.1 M phosphate buffer (PB),
pH 7.4 for 12 h at 4 °C and washed three times for
30 min in 0.1 M PB. Samples were postfixed with 1 %
OsO4 dissolved in 0.1 M PB for 2 h and dehydrated in an
ascending gradual series (50–100 %) of ethanol and
infiltrated with propylene oxide. Specimens were embed-
ded using a Poly/Bed 812 kit (Polysciences, Warrington,
PA, USA). After pure fresh resin embedment and
polymerization at 60 °C in an electron microscope
oven (TD-700, DOSAKA, Kyoto, Japan) for 24 h,
350-nm sections were cut and stained with toluidine
blue for light microscopy and 70-nm thin sections were
double stained with 7 % uranyl acetate and lead citrate for
contrast staining. Sections were made with a LEICA
Ultracut UCT Ultra-microtome (Leica Microsystems,
Wetzlar, Germany). All thin sections were observed by
TEM (JEM-1011, JEOL, Tokyo, Japan) at an acceleration
voltage of 80 kV.
Western blot
Expression of autophagy-related proteins was analyzed
by Western blot. After indicated treatments, A549 cells
were lysed in RIPA lysis buffer (Biosesang, Seongnam,
Gyeonggi, KOREA) with 1 mM PMSF. Equal amounts of
proteins were separated by SDS-PAGE and transferred
to PVDF membranes (Millipore Corporation, Billerica,
MA, USA). After blocking with 5 % nonfat milk, mem-
branes were probed with anti-HIF-1α (BD Biosciences,
San Jose, California, USA), anti-LC3 (Sigma), anti-p62C-
terminus/SQSTM1 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), anti-beclin-1 (Santa Cruz), or anti-β-
actin (Sigma) and developed with ECL (Thermo Scientific,
Rockford, IL, USA) reagent.
NSCLC patients and samples
To determine overexpression of autophagy-related factors
after chemotherapy, we selected five NSCLC patients
(three adenocarcinoma and two squamous cell carcinoma)
who had not yet been treated and five NSCLC patients
(two adenocarcinoma and three squamous cell carcinoma)
who received neoadjuvant treatment before operation as
our study group. All patients underwent complete tumor
resection and mediastinal lymph node dissection at the
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Severance Hospital of Yonsei Medical University. The
research was approved by the Institutional Review Board
of Yonsei University, College of Medicine. All patients
gave signed, informed consent. Tumor specimens and
surrounding normal lung tissue (separated from tumors
by 5 cm) were obtained at surgery, or selected by a path-
ologist, and stored. Specimens were divided into three
groups: protein preparation, TEM and IHC.
Immunohistochemisty for Hypoxia expression
Surgical specimens were immediately transferred from
the operating room to the laboratory, fixed in 10 % for-
maldehyde for four days, and embedded in paraffin.
Formalin-fixed and paraffin-embedded tissues were sec-
tioned at 4 um and stained with antibody against HIF-1α
(ab2185, 1:50, Abcam, Cambridge, UK), Carbonic anhy-
drase IX (CA IX) (ab15086, 1:300, Abcam, Cambridge,
UK) and Glucose transporter 1 (GLUT1) (ab652, 1:100,
Abcam, Cambridge, UK) using a Ventana automated
immunostainer (Ventana Medical Systems, Tucson, AZ)
according to the manufacturer’s protocol. Signals were
detected using a DAB Map detection kit (Ventana
Medical Systems) based on the labeled streptavidin-
biotin method. The frequency of nuclear staining was
evaluated without knowledge of clinical or pathologic
status. Five fields (x200) were analyzed to determine the
frequency of HIF-1α stained nuclei. At least 500 tumor
cells in the five fields were counted. HIF-1α staining was
evaluated using a semiquantitative grading system based
on the number of tumor cells with completely dark stained
nuclei within the tumor tissue (0: none, 1: less than 10 %
positivity, 2: 10 % or greater positivity). Occasional cyto-
plasmic staining was ignored because active HIF-1α is lo-
cated only in the nucleus [14]. Stained slides were graded
independently by a single pathologist (HS Shim).
Protein extraction and Western blotting of tumor tissues
Tumor tissues and adjacent tissues were homogenized
in 1 ml RIPA buffer (50 mM Tris–HCl, pH 7.5, 0.1 %
SDS, 2 mM EDTA, 150 mM NaCl, 1 % sodium deoxy-
cholate, 1 % Triton X-100) and protease inhibitor cock-
tail. Homogenate was incubated for 20 min on ice and
centrifuged at 14,000 rpm for 15 min at 4 °C. Super-
natant was collected and the same volume of 5X SDS
buffer was added. The mixture was boiled for 5 min and
stored at −80 °C. Proteins were separated by sodium
dodecy1 sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) on 8–16 % polyacrylamide gels and transferred to
PVDF membranes (Millipore Corporation, Billerica, MA,
USA), Membranes were blocked in 5 % nonfat milk in
Tris-buffered saline containing 0.05 % Tween-20 (TBST)
at room temperature for 1 h. Membranes were incubated
with rabbit monoclonal antibody against LC3 (1:2000 di-
luted in TBST, Novus, USA) overnight at 4 °C and washed
five times with TBST for 10 min at room temperature.
Membranes were incubated with horseradish peroxidase-
conjugated anti-rabbit secondary antibody (1:2000 dilution
in TBST, Santa Cruz) at 37 °C for 1 h and washed five
times with TBST for 10 min at room temperature.
Membranes were treated with ECL (Thermo Scientific,
Rockford, IL, USA) reagent and exposed to photographic
film. Bands were quantified using densitometry and results
were shown as relative expression of the protein from
different samples compared to a control sample.
Statistical analysis
MTT assays were analyzed using SoftMax Pro5.4
(Molecular Devices Corporation, Sunnyvale, CA, USA).
All experiments were repeated at least three times. Data
were expressed as mean ± standard error of the mean
(SEM). Statistical analysis was performed using Student’s
t-test or ANOVA (two-tailed). The criterion for statistical
significance was p < 0.05.
Results
Hypoxia induces expression of HIF-1α in cancer cells
A549 cells were exposed to 1 % hypoxia for 2, 4, 6 or
8 h, and HIF-1α expression was measured to confirm
Fig. 1 A549 cells exposed to 1 % hypoxia exhibit a time-dependent increase in HIF-1α expression. a: Cells were incubated under 1 % hypoxia for
0, 2, 4, 6 or 8 h. Western blots show HIF-1α expression with longer hypoxia durations. b: Western blot intensity was measured with Image J. Data
are mean ± SEM, *p < 0.05. Graphs represent 7 independent experiments
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hypoxia at each time point by Western blot. HIF-1α pro-
tein started to increase rapidly within 2 h of exposure to
1 % hypoxia and increased further with longer exposure
(Fig. 1).
Hypoxia induces autophagy in cancer cells
Next, we measured autophagy activity under hypoxia.
First, we measured expression from a vector encoding
green fluorescent protein-tagged microtubule-associated
protein 1 light chain 3 (GFP-LC3), which condenses in
autophagic vacuoles, resulting in punctate fluorescence
within cancer cells undergoing autophagy. A549 cells
were transiently transfected with GFP-LC3 plasmids.
After 24 h, cells were exposed to normoxia or hypoxia.
After 8 h of hypoxia, we counted cells with diffuse or
punctate GFP under a confocal microscope. Under nor-
moxia, GFP-LC3 cells were diffusely fluorescent whereas
GFP-LC3 cells showed punctate patterns under hypoxia,
indicating autophagosome formation (Fig. 2a, b).
Using additional independent assays, we confirmed the
involvement of autophagy. We used Western blots to
analyze the conversion of LC3B-I to LC3B-II by protein
processing, which is a hallmark of autophagy. Levels of
endogenous LC3B-I to LC3B-II conversion were substan-
tially increased in A549 cells exposed to 1 % hypoxia com-
pared with cells under normoxia. We also determined
levels of p62/sequestosome1 (SQSTM1), the degradation
of which is used as an autophagy flux marker. Levels of
endogenous p62/SQSTM1 were substantially decreased in
A549 cells exposed to 1 % hypoxia compared with cells
under normoxia (Fig. 2c, d, e).
Transmission electron microscopy (TEM) was used as
another independent assay of autophagy. Cells exposed
to hypoxia showed substantial accumulation of autopha-
gosomes with cytoplasmic organelles and other vesicles
encapsulated in vacuoles (Fig. 2f, g black arrows), sug-
gesting that hypoxia stimulated autophagy and autoph-
agy was enhanced significantly by hypoxia.
Hypoxia enhances cancer cell chemo-resistance
To investigate the influence of hypoxia on chemo-
resistance, A549 cells were exposed to 1 % hypoxia or
normoxia for 8 h in the presence or absence of the che-
motherapeutic agent cisplatin. Cell death determined by
3-[4,5-dimethylthiazol-2yl]-diphenyltetrazolium bromide
(MTT) assays showed that 32.2 % of cells were dead
under normoxia and 11.8 % were dead under 1 % hyp-
oxia with cisplatin (512 μМ) (Fig. 3). These data sug-
gested that under hypoxic condition, A549 cells were
resistant to a chemotherapeutic agent.
Blocking autophagy restores sensitivity of cancer cells to
chemotherapy
To confirm the involvement of autophagy in cancer cells
acquiring resistance to chemotherapy under hypoxia, we
inhibited autophagy using LC3B siRNA in cisplatin-
treated A549 cells. The siRNA restored the sensitivity of
cancer cell to Cisplatin in hypoxia (Fig. 4a). The blocking
of autophagy by siRNA was verified by assaying conversion
of reduced LC3-I to II (Fig. 4b). These results suggested
that activation of autophagy mediated the protective effect
of hypoxia on Cisplatin-induced cell death, and siRNA
targeting LC3B restored chemotherapy-induced cell death
by suppressing autophagy.
Tumor tissues of lung cancer patients experience hypoxia
To confirm the effect of hypoxia on solid tumors, we
investigated whether hypoxia was seen in tumors of
NSCLC patients. HIF-1α expression was assessed by
both immunohistochemistry (IHC) and Western blot
Fig. 3 Hypoxia enhances cancer cell chemoresistance. A549 cells
were treated with indicated concentrations of cisplatin with normoxia
or 1 % hypoxia for 8 h. Cell death was measured by MTT assays.
Percent cell death is shown as mean ± SEM of at least 3 independent
determinations, *p < 0.05
(See figure on previous page.)
Fig. 2 Hypoxia induces autophagy in cancer cells. a: LC3-GFP distribution by confocal microscopy. A549 cells were incubated in normoxia or hypoxia for
8 h. GFP-LC3 showed diffuse intracellular localization under normoxic conditions. Membrane translocation (punctate localization) indicative of autophagy
was observed in hypoxic cells (magnification x40). White arrows, punctate GFP-LC3. b: Quantification of GFP-LC3 translocation in transiently transfected
normoxic and hypoxic cells. The number of GFP-LC3 spots per cell was counted. c: A549 cells were incubated under normoxia or hypoxia for 2, 4, 6 or
8 h. Western blots showed LC3B-I to LC3B-II conversion in A549 cells incubated in 1 % hypoxia compared with normoxia. Expression of the p62 marker
of autophagy flux decreased in A549 cells incubated at 1 % hypoxia compared with normoxia. d, e: Intensity of Western blots measured by Image J.
Graphs represents 6 independent experiments. f: Electron micrographs of A549 cell ultrastructure after normoxia or hypoxia for 8 h. Black
arrows, double-membraned autophagic vacuoles (magnification x20,000). g: Quantification of autophagic vacuoles in normoxic and hypoxic cells. The
number of autophagic vacuoles per cell was counted. N, normoxia; H, hypoxia. Data are mean ± SEM, *p < 0.05
Lee et al. Respiratory Research  (2015) 16:138 Page 5 of 9
and compared with normal lung tissue. Tumors showed
higher expression of HIF-1-α compared with normal
lung tissue on IHC (1.4 vs. 0.2, p < 0.05) (Fig. 5a, b).
Western blots also showed higher expression of HIF-1α
in tumors than in normal lung tissue (Fig. 5c, d).
Besides HIF-1α expression, we also analyzed CA IX
and GLUT1 expression by IHC, which are another hyp-
oxia markers, to confirm the hypoxic condition of
tumor. All normal tissues showed no expression of both
CA IX and GLUT1, but five and eight of ten tumor tis-
sues showed positive expression in CA IX (p < 0.05)
(Fig. 5e) and GLIT1 (p < 0.05) (Fig. 5f ) stain respectively.
These results indicate that hypoxia is a commonly faced
condition in NSCLC tumor.
Chemotherapy enhanced autophagy induction in tumors
of lung cancer patients
To confirm the induction of autophagy in patients with
NSCLC after chemotherapy, we analyzed the conversion
of LC3B-I to LC3B-II. We also analyzed levels of p62/
SQSTM1 in patients with NSCLC who underwent thera-
peutic pulmonary resection after neoadjuvant chemo-
therapy, and patients with NSCLC (chemotherapy naïve)
who underwent only therapeutic pulmonary resection.
Patients who received chemotherapy before pulmonary
resection showed increased LC3B-I to LC3B-II conver-
sion and decreased p62/SQSTM1 compared with pa-
tients who were chemotherapy naïve (Fig. 6). These
results indicated that autophagy was induced by chemo-
therapy in the tumor tissue of NSCLC patients.
Discussion
In this study, we found that hypoxia-induced autophagy
resulted in enhanced cancer cell survival after chemother-
apy. We also confirmed hypoxia and enhanced autophagy
activities in response to chemotherapy in human tumor
tissues. To our knowledge, this is the first study that
demonstrates the role of autophagy especially in hypoxic
condition for the developing chemo-resistance in lung
cancer.
In spite of recent advances in chemotherapeutic
agents, cancer cells show drug resistance that manifests
clinically as tumor progression or recurrence. Although
many studies have analyzed drug resistance, the mecha-
nisms associated with chemotherapy resistance remain
unknown.
Autophagy is important in cellular homeostasis and
facilitating cell survival in adverse conditions [15–19]
including hypoxia [20–23]. The effect of autophagy on
tumors is controversial. Autophagy functions as both a
suppressor and a protector of tumor cells [2, 3]. Specific-
ally, after tumor development, autophagy supports the
persistence of the tumor. Autophagy is documented in
several cancer cells. It is upregulated in response to
therapeutic stress caused by chemotherapy and radiation
[4–6]. In our study, we showed that autophagy contributes
to chemo-resistance in a lung cancer cell line. We also ob-
served enhanced autophagy activity in post-treatment lung
cancer tissue after neo-adjuvant treatment. Most advances
in understanding autophagy and cancer are from studies
using cancer cell lines. Little information is available about
autophagy in clinical tumor samples. To investigate our
hypothesis, we measured autophagy activity in treatment-
naïve tumors and post-treatment tumors from NSCLC pa-
tients after neo-adjuvant treatment. This report describes
enhanced autophagy activity in human lung cancer tissue
after treatment.
Among several conditions that induce autophagy, hyp-
oxia is common microenvironments in solid tumors.
Hypoxia is often found in solid tumors including lung
cancer and is important because it triggers crucial path-
ways related cancer progression. Cells adapt to hypoxia
through several pathways including metastasis, angio-
genesis, autophagy and glycolytic metabolism [24]. Re-
cent studies showed that hypoxia induces autophagy
[21–23], and autophagy induced by hypoxia protects
tumor cells from apoptosis after chemotherapeutic agent
Fig. 4 Knockdown of LC3B restored cancer cells sensitivity to cisplatine under hypoxia. a: A549 cells were transfected with siRNA negative control
or siRNA for LC3B and treated with indicated concentrations of cisplatin under normoxia or hypoxia for 8 h. Cell death was measured by MTT
assays. Percent cell death is shown as mean ± SEM of at least 3 independent determinations. b: Western blots of LC3B-I to LC3B-II conversion in
A549 cells transfected with LC3B siRNA in hypoxia compared with siRNA negative control under normoxia or hypoxia, *p < 0.05
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treatment. Aiming the underlying mechanism of hypoxia,
the HIF-1α-related pathway is crucial [25–29]. HIF-1α,
which is induced by hypoxia, is a main transcription factor
and induces autophagy by controlling expression of the
downstream targets BNIP3 and BNIP3L [30–32]. We
found high expression of HIF-1α in tumor tissues from
NSCLC patients, indicating that hypoxia in solid tumors
was involved in the tumor microenvironment. In addition,
lung cancer cells exposed to hypoxia were resistant to the
chemotherapeutic agent.
Autophagy activities in human solid tumor compared
to normal tissue have been reported in several tumors.
Beclin 1 and LC3 were decreased in human lung cancer
but this expression was not associated with gender,
smoking, histological type and stage [33] and decreased
expression of LC3 was reported in ovarian cancer [34].
However, Yoshioka et al. [35] reported an increased
expression of LC3-II in esophageal and gastrointestinal
tumors, and Karpathiou et al. [36] reported LC3A as a
prognostic factor in lung cancer. In this study, conversion
Fig. 5 Hypoxia markers of tumor tissues of non-small cell lung cancer (NSCLC). a: Immunohistochemical (IHC) stain of tumor tissues shows higher
hypoxia inducible factor 1 α (HIF-1α) expression than normal lung tissue. Red arrow, HIF-1α expression in tumor cell nucleus (magnification x200).
C, cancer; N, normal lung. b: HIF-1α staining scored by a semiquantitative grading system based on tumor cells showing completely dark stained
nuclei: 0, none; 1, less than 10 % positivity; 2, 10 % or greater positivity. Tissues from ten patients were used for analysis. c: Western blots show
higher expression of HIF-1α in tumor tissues of NCSLC. Tumor tissues from patients after treatment or with chemonaïve tumors showing HIF-1α
expression compared with normal lung tissue. N, normal; C, cancer. d: Intensity of Western blots measured using Image J. Tissues from ten patients
were used. Data are mean ± SEM, *p < 0.05. e. Carbonic anhydrase IX (CA IX) expression by IHC. Five of ten tumor tissues showed positive expression,
but no normal tissue showed positive expression (p < 0.05). Red arrow: CA IX expression (magnification x200). C, cancer; N, normal lung. f. Glucose
transporter 1 (GLUT1)) expression by IHC. Eight of ten tumor tissues showed positive expression, but no normal tissue showed positive
expression (p < 0.05). Red arrow: GLUT1 expression (magnification x200). C, cancer; N, normal lung
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of LC3B-I to LC3B-II couldn’t show any difference be-
tween naïve tumor tissues and naïve normal tissues in
Fig. 6. Therefore, the expression of autophagy activity it-
self in several tumors seems not to be clearly understood
yet, and it’s surrounding environments such as exposure
of chemotherapy or radiotherapy look more important as
shown in this study. But further analyses with large
number of cases are needed.
This study has some limitations. Only single tumor
cell line (A549) and single chemotherapeutic agent (cis-
platin) was tested, further experiment with additional
cell line and other chemotherapy agents are needed to
confirm this finding. On top of that, this study focused
on hypoxia induced autophagy activity related to chemo-
resistance. However, hypoxia is also considered to be
associated with inhibition of DNA repair or cell prolifer-
ation that could lead to alter cisplatin sensitivity [37].
Further experiments including several hypoxia related
pathway are needed to understand the underline mech-
anism of this hypoxia related chemo-resistance.
Since hypoxia and autophagy are vital for tumor pro-
gression and effective cancer treatments, we predict that
drugs that alter the hypoxia-autophagy pathway might
be beneficial for improving the responsiveness of chemo-
therapy in cancer patients. Our study demonstrated that
autophagy is pivotal in development of drug resistance
in NSCLC, especially in hypoxic conditions.
Conclusions
Autophagy may play an important role in acquiring
resistance to chemotherapy in lung cancer and hypoxia
related pathway seems to be involved in autophagy
induction.
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Fig. 6 Chemotherapy enhances autophagy in tumor tissues of non-small cell lung cancer (NSCLC). a Western blots for conversion of LC3B-I to
LC3B-II and p62/SQSTM1 in NSCLC tumors after treatment or in non-treated tumor tissues. Also shown, p62 in tumor tissue after treatment compared
to chemotherapy-naïve. b, c: Intensity of Western blots by Image J. Data are mean ± SEM, *p < 0.05. N, normal; C, cancer; neo, neoadjuvant
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